Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Practice

Hepatic sarcoidosis

Toshiyuki Watanabe and Satoshi Jodo
CMAJ August 20, 2018 190 (33) E988; DOI: https://doi.org/10.1503/cmaj.180276
Toshiyuki Watanabe
Internal Medicine, Tomakomai City Hospital, Tomakomai, Japan
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoshi Jodo
Internal Medicine, Tomakomai City Hospital, Tomakomai, Japan
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

A 41-year-old Japanese woman with a six-year history of ocular and pulmonary sarcoidosis had elevated levels of hepatobiliary enzymes, identified during a period health examination (Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.180276/-/DC1). She had no abdominal symptoms or evidence of chronic liver disease, and she had not been taking steroids. Enhanced computed tomography (CT) showed hepatomegaly with multiple mottled low-density lesions (Figure 1A). A positron emission tomography/CT analysis showed diffusely increased hepatic uptake of 18F-fluorodeoxyglucose (FDG) (Figure 1B), and a subsequent liver biopsy showed an accumulation of noncaseating epithelioid granulomas with multinucleated giant cell invasion. We diagnosed hepatic sarcoidosis and prescribed a three-day methylprednisolone pulse of 1 g/d, followed by oral prednisolone 40 mg/d for a month. Because glucocorticoid therapy was only partially effective, we also administered adalimumab (Appendix 2 [Figure A], available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.180276/-/DC1). Subsequently, her liver function returned to normal, and imaging showed a reduction in hepatomegaly and a decrease in low-density areas (Appendix 2 [Figure B]). She has remained in remission for the past two years, with ongoing adalimumab monotherapy.

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

(A) Computed tomography (CT) scan of a 41-year-old Japanese woman with sarcoidosis showing hepatomegaly with multiple mottled low-density lesions. (B) 18F-fluorodeoxyglucose (FDG) positron emission tomography/CT showing the diffuse increment of 18F-FDG uptake in the patient’s liver.

Sarcoidosis is a systemic inflammatory disease of unknown etiology, which is characterized by noncaseating epithelioid granulomas. Sarcoidosis primarily affects the lungs and hilar lymph nodes. The heart, liver and spleen are often involved in extrapulmonary manifestations. Hepatic sarcoidosis has an estimated prevalence of 5%–30% in antemortem cohort studies and 70% in a postmortem study.1 Liver involvement is usually asymptomatic, with normal liver enzyme levels, and abdominal ultrasonography and CT are normal in almost 50% of patients with biopsy-proven hepatic sarcoidosis.1

Positron emission tomography/CT with 18F-FDG is a promising technique to evaluate metabolic activity and is widely accepted for use in detecting active sarcoid lesions.2 Expert consensus supports glucocorticoids as first-line therapy, with tumour necrosis factor inhibitors, including adalimumab, reserved for glucocorticoid-resistant cases.3

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

  • The authors have obtained patient consent.

References

  1. ↵
    1. Ungprasert P,
    2. Crowson CS,
    3. Simonetto DA,
    4. et al
    . Clinical characteristics and outcome of hepatic sarcoidosis: a population-based study 1976–2013. Am J Gastroenterol 2017;112:1556–63.
    OpenUrl
  2. ↵
    1. Sobic-Saranovic D,
    2. Grozdic I,
    3. Videnovic-Ivanov J,
    4. et al
    . The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med 2012;53:1543–9.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Jamilloux Y,
    2. Cohen-Aubart F,
    3. Chapelon-Abric C,
    4. et al.
    Groupe Sarcoïdose Francophone. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients. Semin Arthritis Rheum 2017;47: 288–94.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 190 (33)
CMAJ
Vol. 190, Issue 33
20 Aug 2018
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hepatic sarcoidosis
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hepatic sarcoidosis
Toshiyuki Watanabe, Satoshi Jodo
CMAJ Aug 2018, 190 (33) E988; DOI: 10.1503/cmaj.180276

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Hepatic sarcoidosis
Toshiyuki Watanabe, Satoshi Jodo
CMAJ Aug 2018, 190 (33) E988; DOI: 10.1503/cmaj.180276
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • SARS-CoV-2 vaccination in pregnancy
  • Infantile perianal pyramidal protrusion
  • Topical nonsteroidal anti-inflammatory drugs
Show more Practice

Similar Articles

Collections

  • Article Types
    • Clinical Images
  • Topics
    • Imaging
    • Rheumatology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire